This article is more than 5 years old. Information may no longer be current.

FDA clears knee implant system for osteoarthritis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Blue Belt Technologies Inc. received 510(k) clearance from the FDA to market its Stride Unicondylar Knee implant system.

According to a company press release, the Stride Unicondylar Knee system is available for treatment of both medial and lateral compartment osteoarthritis. It will be co-marketed with Blue Belt Technologies’ NavioPFS precision orthopedic surgical system, which has been commercially available in the United States since December 2012.

“We are excited to be able to offer the Stride implant on our NavioPFS surgical system. Our design team, led by Dr. Jess Lonner, focused on optimizing the Stride implant to integrate seamlessly with the NavioPFS system,” Eric B. Tomiko, president and chief executive officer of Blue Belt Technologies, stated in the release. “We remain focused and committed to continuing to build our NavioPFS’s open architecture for implant selection. Allowing our customers to adopt technology while continuing to maintain their long-term existing relationships with implant manufacturers will allow Blue Belt to reach a wider physician audience.”